Compare Medpace Holdings Inc (MEDP) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Teradyne, Inc. — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.82B), while Teradyne, Inc. trades at $407 (market cap $62.34B). The key difference: Teradyne, Inc. is far larger — about 3.7× Medpace Holdings Inc's market cap, and Teradyne, Inc. pays a 0.13% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Teradyne, Inc. for 37 Days on average.
| MEDP | TER | |
|---|---|---|
Market Cap | $16.82B | $62.34B |
Volume | 223,093 | 3,368,404 |
Sector | Health | Technology |
52-Week High | $630.19 | $483.84 |
52-Week Low | $393.42 | $132.05 |
Typical Hold Time | 14 Days | 37 Days |
Enterprise Value | $16.44B | $62.08B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Teradyne (TER) trades at $411.78, down 4.31% today but maintains strong technical momentum with bullish moving averages and support at $407. The company demonstrates robust fundamentals with 59.24% gross margins and consistent earnings beats, including Q2 2026 EPS of $2.47 versus $2.09 expected. Recent product launches like Magnum E2 and Iris 100 position TER to capitalize on AI-driven semiconductor testing demand.
TER offers compelling growth potential with 61% analyst buy ratings and a $461.50 price target representing 12% upside. However, elevated valuations (P/E 56.56) and cyclical semiconductor exposure present risks. The stock's outlook remains positive driven by AI infrastructure spending and expanding test portfolio, though investors should monitor competitive pressures and industry demand cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
